Denali Therapeutics wins 2026 Prix Galien USA Award for AVLAYAH®, first FDA-approved biologic crossing blood-brain barrier

Denali Therapeutics' AVLAYAH® (tividenofusp alfa-eknm), the first FDA-approved biologic designed to cross the blood-brain barrier, won the 2026 Prix Galien USA Award for Best Biotechnology Product. Approved in March 2026 for treating neurologic symptoms of Hunter syndrome in pediatric patients, AVLAYAH represents a breakthrough in delivering therapies to the brain. Denali’s proprietary TransportVehicle™ technology enables this delivery and is being developed for other diseases like Alzheimer’s. This award highlights the drug's scientific innovation and potential to transform care for rare genetic and neurodegenerative diseases.

Denali Therapeutics Inc. (DNLI) shares trade at USD 19.49 on Pluang as of Oct 30, 2026 20:41 WIB. The stock gained 0.88% in one day with a market cap of $3.09 billion. Investors hold the stock typically for 15 days, reflecting steady interest in this health sector company.